行情

ARNA

ARNA

阿里纳制药
NASDAQ

实时行情|Nasdaq Last Sale

45.81
+0.39
+0.85%
盘后: 45.81 0 0.00% 16:41 11/15 EST
开盘
45.84
昨收
45.43
最高
46.34
最低
45.18
成交量
26.82万
成交额
--
52周最高
64.48
52周最低
35.04
市值
22.95亿
市盈率(TTM)
4.245
分时
5日
1月
3月
1年
5年

分析师评级

10位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

ARNA 新闻

  • Everest Medicines Achieved First Patient Dosing Milestone in Etrasimod Phase 3 Clinical Study in Ulcerative Colitis Patients in Asia
  • GlobeNewswire.2天前
  • Benzinga's Top Upgrades, Downgrades For November 13, 2019
  • Benzinga.3天前
  • Bank of America Initiates Coverage On Arena Pharmaceuticals with Neutral Rating, Announces $51 Price Target
  • Benzinga.3天前
  • BofAML likes Alnylam in premarket analyst action
  • Seeking Alpha - Article.3天前

更多

所属板块

生物技术和医学研究
+1.25%
制药与医学研究
+1.34%

热门股票

名称
价格
涨跌幅

ARNA 简况

Arena Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing small molecule drugs across a range of therapeutic areas. The Company has three primary investigational clinical programs: etrasimod (APD334) in Phase II evaluation for ulcerative colitis, APD371 entering Phase II evaluation for the treatment of pain associated with Crohn's disease, and ralinepag (APD811) in Phase II evaluation for pulmonary arterial hypertension (PAH). The Company's drug, Lorcaserin, is approved for marketing in the United States and South Korea for the indication of weight management. The Company's drug candidates in clinical development include APD334 for autoimmune diseases, ralinepag for vascular diseases and APD371 for pain. The Company's programs under collaboration include nelotanserin for dementia-associated psychosis, temanogrel for thrombotic diseases, and an undisclosed orphan GPCR for central nervous system (CNS) indication(s).
展开

Webull提供Arena Pharmaceuticals, Inc.的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。